PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME
본 발명은 적어도 하나의 대사 증후군 및/또는 죽상 동맥경화증, 특히 당뇨병, 이상지질혈증, 비만증 및/또는 지방과다증의 치료를 위한 적어도 하나의 FGF-21(섬유아세포 성장 인자 21) 화합물, 적어도 하나의 GLP-1R(글루카곤-유사 펩티드-1 수용체) 작용제 및 임의로 적어도 하나의 항-당뇨병 약물 및/또는 적어도 하나의 DPP-4(디펩티딜 펩티다제-4) 억제제를 함유하는 약제학적 조성물에 관한 것이다. The invention is directed to a pharmaceutical composition containing...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SOMMERFELD MARK SCHAEFER HANS LUDWIG RAO ERCOLE DREYER MATTHIAS BOSCHEINEN OLIVER HABERMANN PAUL |
| description | 본 발명은 적어도 하나의 대사 증후군 및/또는 죽상 동맥경화증, 특히 당뇨병, 이상지질혈증, 비만증 및/또는 지방과다증의 치료를 위한 적어도 하나의 FGF-21(섬유아세포 성장 인자 21) 화합물, 적어도 하나의 GLP-1R(글루카곤-유사 펩티드-1 수용체) 작용제 및 임의로 적어도 하나의 항-당뇨병 약물 및/또는 적어도 하나의 DPP-4(디펩티딜 펩티다제-4) 억제제를 함유하는 약제학적 조성물에 관한 것이다.
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20180049194A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20180049194A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20180049194A3</originalsourceid><addsrcrecordid>eNrjZLAJ8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH091Nw8w9SCAlydQzx9HNXcFTwdQ1xdPL38XRWCI70cwny93XlYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx3kFGBoYWBgYmloaWJo7GxKkCAMYkKqk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME</title><source>esp@cenet</source><creator>SOMMERFELD MARK ; SCHAEFER HANS LUDWIG ; RAO ERCOLE ; DREYER MATTHIAS ; BOSCHEINEN OLIVER ; HABERMANN PAUL</creator><creatorcontrib>SOMMERFELD MARK ; SCHAEFER HANS LUDWIG ; RAO ERCOLE ; DREYER MATTHIAS ; BOSCHEINEN OLIVER ; HABERMANN PAUL</creatorcontrib><description>본 발명은 적어도 하나의 대사 증후군 및/또는 죽상 동맥경화증, 특히 당뇨병, 이상지질혈증, 비만증 및/또는 지방과다증의 치료를 위한 적어도 하나의 FGF-21(섬유아세포 성장 인자 21) 화합물, 적어도 하나의 GLP-1R(글루카곤-유사 펩티드-1 수용체) 작용제 및 임의로 적어도 하나의 항-당뇨병 약물 및/또는 적어도 하나의 DPP-4(디펩티딜 펩티다제-4) 억제제를 함유하는 약제학적 조성물에 관한 것이다.
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.</description><language>eng ; kor</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180510&DB=EPODOC&CC=KR&NR=20180049194A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20180510&DB=EPODOC&CC=KR&NR=20180049194A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SOMMERFELD MARK</creatorcontrib><creatorcontrib>SCHAEFER HANS LUDWIG</creatorcontrib><creatorcontrib>RAO ERCOLE</creatorcontrib><creatorcontrib>DREYER MATTHIAS</creatorcontrib><creatorcontrib>BOSCHEINEN OLIVER</creatorcontrib><creatorcontrib>HABERMANN PAUL</creatorcontrib><title>PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME</title><description>본 발명은 적어도 하나의 대사 증후군 및/또는 죽상 동맥경화증, 특히 당뇨병, 이상지질혈증, 비만증 및/또는 지방과다증의 치료를 위한 적어도 하나의 FGF-21(섬유아세포 성장 인자 21) 화합물, 적어도 하나의 GLP-1R(글루카곤-유사 펩티드-1 수용체) 작용제 및 임의로 적어도 하나의 항-당뇨병 약물 및/또는 적어도 하나의 DPP-4(디펩티딜 펩티다제-4) 억제제를 함유하는 약제학적 조성물에 관한 것이다.
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAJ8HAM8nV0dg0N8XR29FFw9vcN8A_2DPH091Nw8w9SCAlydQzx9HNXcFTwdQ1xdPL38XRWCI70cwny93XlYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx3kFGBoYWBgYmloaWJo7GxKkCAMYkKqk</recordid><startdate>20180510</startdate><enddate>20180510</enddate><creator>SOMMERFELD MARK</creator><creator>SCHAEFER HANS LUDWIG</creator><creator>RAO ERCOLE</creator><creator>DREYER MATTHIAS</creator><creator>BOSCHEINEN OLIVER</creator><creator>HABERMANN PAUL</creator><scope>EVB</scope></search><sort><creationdate>20180510</creationdate><title>PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME</title><author>SOMMERFELD MARK ; SCHAEFER HANS LUDWIG ; RAO ERCOLE ; DREYER MATTHIAS ; BOSCHEINEN OLIVER ; HABERMANN PAUL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20180049194A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; kor</language><creationdate>2018</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>SOMMERFELD MARK</creatorcontrib><creatorcontrib>SCHAEFER HANS LUDWIG</creatorcontrib><creatorcontrib>RAO ERCOLE</creatorcontrib><creatorcontrib>DREYER MATTHIAS</creatorcontrib><creatorcontrib>BOSCHEINEN OLIVER</creatorcontrib><creatorcontrib>HABERMANN PAUL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SOMMERFELD MARK</au><au>SCHAEFER HANS LUDWIG</au><au>RAO ERCOLE</au><au>DREYER MATTHIAS</au><au>BOSCHEINEN OLIVER</au><au>HABERMANN PAUL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME</title><date>2018-05-10</date><risdate>2018</risdate><abstract>본 발명은 적어도 하나의 대사 증후군 및/또는 죽상 동맥경화증, 특히 당뇨병, 이상지질혈증, 비만증 및/또는 지방과다증의 치료를 위한 적어도 하나의 FGF-21(섬유아세포 성장 인자 21) 화합물, 적어도 하나의 GLP-1R(글루카곤-유사 펩티드-1 수용체) 작용제 및 임의로 적어도 하나의 항-당뇨병 약물 및/또는 적어도 하나의 DPP-4(디펩티딜 펩티다제-4) 억제제를 함유하는 약제학적 조성물에 관한 것이다.
The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; kor |
| recordid | cdi_epo_espacenet_KR20180049194A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T04%3A48%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SOMMERFELD%20MARK&rft.date=2018-05-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20180049194A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |